Action(s) taken or orders passed
As filed · SMS Pharmaceuticals Limited has informed the Exchange about Action(s) taken or orders passed
What happened
FactAction(s) taken or orders passed. demand of Rs.45.63 Crores, including interest, stands vacated.
Why it matters
CapitSignal interpretationAn order converts to revenue over its execution period, so its size relative to existing revenue decides whether it changes the trajectory or is routine flow.
Scale
- 5.1% of FY26 revenue
₹45.63 Cr stated in the filing against ₹886.87 Cr revenue (FY26, standalone)
Source: financial_facts · exchange_table
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Demand
RevisedOur revenue reached ₹783 crore, marking a 10% increase over the previous year, supported by steady demand across our therapeutic portfolio.
Anti-inflammatory products, led by ibuprofen, grew 22% year-on-year to ₹148 crore.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Execution period stated in the order
- Whether the order book total is disclosed
- Margin commentary at the next results
- Aim to add 8-10 products in the next 12-18 months in existing and new therapeutic areas (management committed by H1 FY27)
- Looking ahead, we are building a robust pipeline of high-potential molecules. (management committed by H1 FY27)
Evidence
- SMS Pharmaceuticals Limited has informed the Exchange about Action(s) taken or orders passed(opens the original filing in a new tab)
- Earlier statement · FY25
- Latest statement · FY25
- Earlier statement · FY25
How CapitSignal classified this
- Reasoning:
- ORDER_WIN base 58; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%